Figures
Abstract
Purpose
To investigate the efficacy of leflunomide in experimental autoimmune uveitis (EAU) in rats.
Methods
Lewis rats were immunized with interphotoreceptor retinoid-binding peptide (IRBP) in order to generate EAU. Rats received three dose of leflunomide through intragastric administration (prevention or treatment protocols) after immunization at three separate doses (3 mg/kg/d; 6 mg/kg/d; 12 mg/kg/d). Cyclosporin A was administered as a positive) control. Rats were euthanized during peak disease activity (day 14 or 15). Treatment effectiveness was evaluated in vivo using clinical EAU scoring (d14) and histopathological evaluation of enucleated eyes after experimental termination. The expression levels of inflammatory cytokines in the serum were quantified by ELISA. Eyeball of rats were harvested and mRNA expression of interleukin 17 (IL17) and IFN-γ were quantified through RT-PCR. Intracellular expression of interleukin (IL)-17 in the activated CD4(+) T cells was assessed by flow cytometry. The effects of leflunomide inhibition on immune responses in rats were investigated in isolated lymphocytes.
Results
Histopathological and clinical data revealed severe intraocular inflammation in the immunized rat. Inflammation reached its peak on day 14 in this EAU model. Treatment with leflunomide significantly prevented and treated EAU-induced ocular inflammation and decreased clinical and pathological scores compared to vehicle-treated eyes. Gene expression of IL17 and IFN-γwas markedly reduced in leflunomide-treated eyes. Leflunomide significantly decreased the serum levels of IL17 and IFN-γ. The study of IL17+ T cells in peripheral blood and spleen by flow cytometry showed a decreased number of Th17 cell in rats of leflunomide prevented group. Lymphocytes from animals treated with leflunomide had decreased antigen-specific proliferation in vitro compared with lymphocytes from untreated animals.
Citation: Fang C-b, Zhou D-x, Zhan S-x, He Y, Lin Z, Huang C, et al. (2013) Amelioration of Experimental Autoimmune Uveitis by Leflunomide in Lewis Rats. PLoS ONE 8(4): e62071. https://doi.org/10.1371/journal.pone.0062071
Editor: James T. Rosenbaum, Oregon Health & Science University, United States of America
Received: October 31, 2012; Accepted: March 17, 2013; Published: April 23, 2013
Copyright: © 2013 Fang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Natural Science Foundation of China Grant (No. 81273525, No. 81272686). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Uveitis, which is defined as inflammation of the middle vascular layer of the eye, is one of the most common causes of blindness and visual impairment worldwide [1]. Human autoimmune uveoretinitis is thought to be caused either by an autoimmune response or by an unknown etiology [2], [3].
Experimental autoimmune uveitis (EAU) is an animal model representing human autoimmune uveitis. This experimental model is useful for determining the cause of human posterior uveitis and for developing new therapeutic strategies [4], [5], [6]. EAU is predominantly a T-cell-mediated disease. A Th1 response is thought to be an essential factor in EAU pathogenesis. Recent evidence suggests that newly recognized interleukin (IL)-17, produced by T helper IL-17 cells, plays a crucial role in the disease progress of EAU, and that a Th1 and Th17 response are differentially required for EAU development [7], [8], [9], [10], [11].
Leflunomide (LEF), a new disease-modifying antirheumatic drug of the isoxazol family, is clinically used in the treatment of rheumatoid arthritis, sarcoidosis, solid organ transplantation, lupus nephritis and the course of several autoimmune diseases [12], [13], [14]. Korn et al. gave leflunomide orally at 20 mg/kg per day completely protected the rats from clinically apparent EAN [15]. The primary metabolite of leflunomide reversibly inhibits dihydroorotate dehydrogenase, which leads to diminished DNA synthesis and impaired proliferative capacity [16]. Unlike other cells, activated lymphocytes expand their pyrimidine pool by eight to sixteen-fold during proliferation and must use both salvage and de novo pathways of synthesis to meet this metabolic demand. In the presence of leflunomide, T cell proliferation is inhibited [17], [18]. By decreasing the supply of pyrimidines, leflunomide leads to the interruption of the cell cycle and decreased proliferation of activated lymphocytes. Therefore, leflunomide (LEF) is an interesting potential therapeutic agent in the treatment of EAU.
Despite its known immunomodulatory effects, there are very few studies regarding the role of LEF in uveitis [19], [20], [21]. However, in animal studies administration of leflunomide resulted in the inhibition of IFN- γ production [22], [23]. In this study, the efficacy of leflunomide was determined in the rodent EAU model. Leflunomide strikingly ameliorated both the clinical symptoms and the pathologic manifestations during peak phases of the disease. We report the successful use of leflunomide for the prevention and treatment of EAU and the effective inhibition of Th17 responses in Lewis rats.
Methods
Animals
Female Lewis rats, 6–8 weeks old, were purchased from Vital River (Beijing, China) and housed in SPF conditions for 1 week prior to experimentation. The animals had access to food and water ad libitum. All animal experiments were approved by the Laboratory Animal Care and Use Committee of the Anhui Medical University and adhere to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Drugs and Reagents
The interphotoreceptor retinoid binding protein peptides spanning amino acid residues 1169–1191 (IRBP1169–1191, PTARSVGAADGSSWEGVGVVPDV) were synthesized and purified by Shanghai Sangon Biological Engineering Technology & Services Ltd. Co. Complete Freund’s Adjuvant, Pertussis toxin Ficoll-Hypaque gradient reagent, and 3-(4,5-dimethylthylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) powder were purchased from Sigma-Aldrich Chemical (St. Louis, USA). Leflunomide was purchased from Cinkate Pharmaceutical (Shanghai, China). RPMI-1640 medium (pH adjusted to 7.2) was purchased from Gibco (USA) and was supplemented with 25 mmol/L Hepes, 2 mmol/L L-glutamine, 50 µmol/L 2-mercaptoethanol, 100 IU/L penicillin sodium, 100 IU/L streptomycin, and 1 mmol/L sodium pyruvate. All other chemicals and solvents were purchased from local firms (Hefei, China) and were at the highest purity and analytical grade.
Induction of EAU and Treatment Protocols
On day 0, Lewis rats were immunized with 100 µg IRBP peptide emulsified in CFA. The emulsion was injected into one hind footpad in a total volume of 0.1 ml and Pertussis toxin (400 ng) was given intraperitoneally as an additional adjuvant.
Leflunomide, in powder form, was dissolved in 0.5% carboxymethyl cellulose. Cyclosporin A (CsA) was solubilized in olive oil at 25 mg/mL. Therapeutic agents were leflunomide (administered in low [3 mg/kg], medium [6 mg/kg], and high [12 mg/kg] doses), CsA (positive control, 10 mg/kg), and vehicle (negative control, physiological saline). Rats were divided into two main treatment groups, preventive and therapeutic. Preventively treated rats were divided into six treatment groups. Treatment with leflunomide in a volume of 1.0 ml carboxymethyl cellulose was given orally by gavage from day (d) 1 to d13 post-immunization. Cyclosporin A was gavaged at 10 mg/kg from d1 to d13 post-immunization. Negative controls were gavaged with physiological saline only. Treatments in the therapeutic rats were delivered daily in the same manner, but treatments began from d8 with respect to IRBP immunization. Each treatment group consisted of six to eight rats. Experiments were performed twice.
Clinical Evaluation of EAU and Scoring
Clinical assessment by slit lamp microscopy examination of ocular inflammation was conducted every day from day 7 after immunization. Each eye was graded, without masking, according to a previously described scoring system: 0, normal; 0.5, dilated blood vessels in the iris; 1, abnormal pupil contraction; 2, hazy anterior chamber; 3, moderately opaque anterior chamber with dull red reflex; 4, opaque anterior chamber, absent red reflex, and proptosis [24].
Histopathological Evaluation of EAU and Scoring
Animals were euthanized during peak disease activity (day 14 or 15), and the eyes were enucleated, fixed in 4% buffered paraformaldehyde, embedded in paraffin, sectioned (4–6 µm) through the papillary-optic nerve plane, and stained with hematoxylin and eosin. Presence or absence of disease was evaluated blindly by examining six sections sectioned at different levels for each eye. Severity of EAU was scored on a scale of 0 (no disease) to 4 (maximum disease) in half-point increments based on the presence of inflammatory cell infiltration of the iris, ciliary body, anterior chamber, and retina (0 = normal anterior segment and retinal architecture, with no inflammatory cells in these structures; 1 = mild inflammatory cell in filtration of the anterior segment and retina; 2 = moderate inflammatory cell infiltration of the anterior segment and retina; 3 = massive inflammatory cell in filtration of the anterior segment and retina, disorganized anterior segment and retina; and 4 = as in 3 but with photoreceptor cell damage) [25], [26]. No information about the experimental design or treatments was provided to the pathologist.
Lymphocyte Proliferation Assay and In Vitro Suppression
At the termination of the experiment on d14 after immunization, spleens and draining lymph nodes were harvested. The lymphocytes were prepared by pushing spleens through a 100 µm nylon mesh. Lymphocytes from spleen and draining lymph node cell suspensions were isolated by Ficoll-Hypaque gradient centrifugation. Cells (100 µL, at a final density of 2 × 105 cells/well ) from Lewis rats were stimulated with 10 µg/mL IRBP in 96-well culture plate in triplicate in a humidified 5% CO2 atmosphere at 37°C for 48 h. MTT reagent (10 µL/well, at a final concentration of 5 g/L) was pulsed into each well 6 h before termination of culture. At the end of culture, the cells were centrifuged at 1000×g for 10 min and supernatants discarded. DMSO (150 µL) was added to each well and oscillated for 30 s to dissolve the formazan crystals. Optical density (OD) values were detected using a microplate reader (MK3, Lebo, Dutch) at a wavelength of 570 nm, and the results were presented as the average of triplicate absorbance.
Semi-quantitative Reverse Transcription-polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from the freshly isolated retinas of every group at the end of the experiment (day 14) using Trizol (Invitrogen, Carlsbad, USA) reagent according to the manufacturer’s protocol. The first strand of cDNA was synthesized using total RNA (1 µg/reaction), which was incubated at 70°C for 10 min and then chilled on ice immediately. Then 4 µL of 25 mmol/L MgCl2, 2 µL of reverse transcription buffer, 2 µL of 10 mmol/L dNTP mixture, 0.5 µL recombinant RNasin ribonuclease inhibitor, 15 U AMV reverse transcriptase, 0.5 µL oligo(dT) primer, and 8.4 µL nuclease-free water were added. The mixture was incubated at 42°C for 1 h, heated at 95°C for 5 min, and then incubated at 4°C for 5 min. cDNA (50–100 ng) was amplified using primers (Sango, Shanghai, China) specific for rat IL-17, IFN-γ, and β-actin. Primer sequences and optimal PCR annealing temperatures and cycle numbers are listed in Table 1. PCR was carried out for 35 cycles according to the following procedure: at 94°C for 40 s, annealing for 40 s, and at 72°C for 40 s. The PCR products were subjected to 1.5% agarose gel electrophoresis and semi-quantified by OD with an Image-Pro Plus software program (Ipwin 32, Medis Cybernetics, USA). RNA expression was quantified by comparison with the internal control β-actin.
Cytokine Assay
Serum was collected from every group at the end of the experiment. Cytokines IFN-gamma and IL-17 were measured using commercially available ELISA kit according to the manufacturer’s instructions. To assess the intraocular cytokine IL17, snap-frozen eyes were mechanically homogenized, resuspended in 1 ml PBS with proteinase inhibitors(Leupeptin(10 uM), Pepstatin A(1 uM) and phenylmethanesulfonyl fluoride(1 mM). sonicated and centrifuged at 12,000 rpm for 5 min. The supernatant was stored at –80°C until use.
Flow Cytometric Analysis
On days 14 after immunization we investigated the frequency of IL17+T cells. Individual cell suspensions from the spleen and peripheral mononuclear blood cells (PBMC) were prepared. Aliquots of 1×106 T cells were pre-cultured with Brefeldin A (BFA, 0.5 mg/ml; ENZO, USA), ionomycin (5 μg/ml; ENZO, USA), and phorbol-12-myristate-13-acetate (PMA, 50 ng/ml; ENZO, USA) for four hours before intracellular staining. After permeabilization, Th17 cells were stained with PE-labeled anti-mouse IL-17 antibodies (eBioscience, USA) and fluorescein isothiocyanate (FITC)-labeled anti-rat CD4 Abs (eBioscience, USA).
Data collection and analysis were performed with a flow cytometer (FACSCalibur; BD PharMingen) and appropriate software (CellQuest; BD PharMingen).
Statistical Analysis
Experiments were performed at least two times. Disease severity for each animal was calculated as an average of both eyes. Data are presented as mean ± standard deviation (SD). EAU scores were compared by the Mann-Whitney U test. Continuous variables from the other experiments were analyzed with the unpaired Student’s t-test. P<0.05 was considered to be statistically significant. The mean values of treatment groups were compared with one-way ANOVA. When the ANOVA showed that there were significant differences (P<0.05) between the groups, a Dunnett’s test or Bonferroni’s test was used to identify the sources of these differences. This secondly obtained P value was considered statistically significant when P<0.05.
Results
EAU Model: Clinical Scoring
Daily oral administration of leflunomide prevented visible clinical signs of EAU development in comparison with vehicle treated controls. On day 14, vehicle group rat showed severe inflammation (mean clinical score, 3.4±0.5; n = 8.) There was a statistical difference in the mean clinical scores between the vehicle group and low dose group with leflunomide(mean clinical score, 1.6±0.5; n = 8, p<0.001) (Fig. 1A). All doses of leflunomide were effective at preventing clinically significant uveitis in a dose-dependent manner. The medium [6 mg/kg], and high [12 mg/kg] doses provided a greater protection than the low dose (Fig. 1A). More important, we observed dose-dependent effectiveness of leflunomide in animals that received gavage after disease onset (d8– d13; Fig. 1A). The leflunomide treatment led to a significant reduction of the clinical severity of EAU from day 14 after immunization compared to rats that received injections of physiological saline.
(A) Rats were immunized with IRBP (d0) to induce uveitis and intragastric administration (d1–d13) with leflunomide (low dose, 3 mg/kg; medium dose, 6 mg/kg; high dose, 12 mg/kg) or CsA (10 mg/kg). At the time of oral administration, mean clinical scores were recorded (d13) and are represented as mean clinical scores ±SD. Data presented are the average of six to eight rats per group. Clinical scores were calculated by the nonparametric Mann-Whitney U test. Statistical significance compared with vehicle is indicated by asterisks (*P<0.05; **P<0.01; ***P<0.001). (B) The slit-lamp biomicroscopic of the eyes of different groups on day 14 after immunization. (a) Normal group rats eye showed normal iris vessels and red reflex. (b) Vehicle treated rats showed severe iris hyperemia and occlusion of pupil (c) leflunomide (low dose, 3 mg/kg). (d) leflunomide (medium dose, 6 mg/kg). (e) leflunomide (high dose, 12 mg/kg). (f) CsA (positive control, 10 mg/kg).
As shown in Figure 1B, most of the IRBP-treated rats shown severe illness developed including opaque anterior chamber obscured pupil(Fig. 1B.b). Peak clinical scores of 3 and 4 were observed on day 14. In group treated simultaneously with immunization, leflunomide orally strikingly reduced disease severity, and leflunomide treated rats showed only slight signs of anterior chamber inflammation especially the medium and high dose (Fig. 1B. d–e). In addition, the early clinical signs of EAU in the control group, including engorged blood vessels in the iris and abnormal pupil contraction, were primarily found from day 8, whereas in rats treated early with leflunomide, the onset of clinical EAU was delayed to day 11.
EAU Model: Histopathology
Masked evaluation of histopathology after experimental termination of in vivo experiments also revealed dose-dependent efficacy of leflunomide. Histopathology of eyes collected on day 14 revealed that vehicle-treated rats showed retinal disorganization; photoreceptor destruction and inflammatory cells in the vitreous, uvea, and retina (Fig. 2A.b). Leflunomide preventively treated rats had significantly milder pathologic severity of the retina compared to the untreated control rats (Fig. 2A. c–e). Extensive ocular inflammation and photoreceptor destruction was observed in eyes of the vehicle-treated rats (Fig. 2A.b), which had the highest combined anterior and posterior histopathologic scores. Retinas from vehicle-treated rats had marked inflammatory infiltration, focal destruction of the nuclear layers that were more prominent in the outer nuclear layer, and total loss of inner and outer photoreceptor segments. Compared with vehicle-treated controls, a significant reduction in the median EAU scores were observed in the eyes from the low, medium, and high leflunomide preventively treated rats (Fig. 2B). On day 14, when the disease was at its peak pathological score (approximately 3.4), leflunomide preventively treated rats given the low dose of leflunomide had a score of nearly 2.5, which was significantly lower (P<0.05) than control rats.
(A) Representative histopathology of EAU in the different treatment groups. At the termination of the experiment, eyes were fixed and embedded in paraffin. Retinal tissue sections (×100) stained with hematoxylin and eosin. (a) the retina of a normal rat eye. (b) vehicle, physiological saline. (c) leflunomide (low dose, 3 mg/kg). (d) leflunomide (medium dose, 6 mg/kg). (e) leflunomide (high dose, 12 mg/kg). (f) CsA (positive control, 10 mg/kg). Black arrows: inflammatory cellular infiltrates surrounding retinal vessels and in the vitreous. (B) Effect of leflunomide on histopathology of rats with EAU. Histology scores in rats on day 14 after immunization of different groups showed significant histologic improvement in groups. Histology scores were calculated by the nonparametric Mann-Whitney U test. Values are expressed as mean ±SD. (*P<0.05; **P<0.01; ***P<0.001) (n = 8).
All animals in the low-dose leflunomide therapeutic treatment group exhibited uveitis, including retinal folds and small granuloma formation (Fig. 2A.g, black arrows). Retinal inflammatory cellular infiltration was obviously alleviated in medium-dose and high-dose leflunomide therapeutic treatment groups(Fig. 2A.h).
Leflunomide Suppression of Lymphocyte Proliferation
Along with suppression of intraocular inflammation, in vitro proliferation of lymphocytes determined from rats treated with leflunomide. Lymphocyte proliferation was significantly suppressed in cultures stimulated with IRBP (Fig. 3).
The proliferation of cultured cells was examined by MTT assay. Results are expressed as mean±SD (n = 8). *P<0.05, **P<0.01.
Effects of Leflunomide on Chemokine mRNA Expression in the Retina
As Fig. 4A shows, there was significant difference in the mRNA of IL17 and IFN-γ between the leflunomide-treated and the vehicle-treated eyes. The medium and high doses provided more statistically significant protection than the low dose. Thus, these data suggest that an orally administered leflunomide suppresses the mRNA expression of IL17 (Fig. 4B) and IFN-γ(Fig. 4C) in the eyes with ongoing ocular inflammation.
The mRNA levels were normalized to those of β-actin(Figure 4A). RT-PCR analysis reveals that the mRNA expression of IL17 and IFN-γwere significantly increased in IRBP-treated rats. In contrast, leflunomide treatment reduced the expression of IL17 and IFN-γin EAU rats(Figure 4B,4C). Data are expressed as the mean±SD (n = 8). *P<0.05; **P<0.01; ***P<0.001. 1, normal; 2, vehicle; 3, low-dose leflunomide (3 mg/kg); 4, medium-dose leflunomide (6 mg/kg); 5, high-dose leflunomide (12 mg/kg); 6, CsA (10 mg/kg).
Analysis Cytokines IFN-r and IL-17 Levels in EAU and Treated with Leflunomide
We examined whether oral administered of leflunomide suppressed the production of inflammatory cytokine, IL17 and IFN-γin the serum of immunized rats, IL17 in the eyes of immunised rats. As fig. 5 shows, on day 14, the production of IFN-γ (Fig. 5A) and IL17 (Fig. 5B) was markedly suppressed in the leflunomide-treated serum by ELISA (P<0.05). As Fig. 5C shows, on day 14, the production of IL17 was markedly suppressed in the leflunomide-treated eyes (P<0.05). These results suggest that leflunomide has the capacity to suppress inflammatory cytokine levels in serum and eyes with ongoing EAU.
leflunomide significantly decreased the serum production of IFN-gamma and IL17. Comparison between groups was made using one-way ANOVA; *P<0.05; **P<0.01; The level of IL17(Fig. 5C) in the eye on day 14 were quantified by ELISA. leflunomide significantly decreased ocular production of IL17. Comparison between groups was made using one-way ANOVA; *P<0.05; **P<0.01.
Detection of Th17 Cells in EAU and Effect of Leflunomide Blockade against Murine Th17 Cells
On day 14 after immunization, rats were sacrificed and spleen cells and PBMC were collected. As expected, the spleens and PBMC from EAU donors contained significant numbers of CD4+IL-17+Th17-type T cells. By contrast, fresh splenic and PBMC CD4+T cells from normal non-immunized rats had only a small population of IL-17+cells(Fig. 6A–6D). T cells from vehicle group produced large amounts of IL-17 in the presence of IRBP peptide in vitro(Fig. 6A, Fig. 6C). Rats showed a marked decreased in IL17+T cells in spleen and PBMC after treated with leflunomide. These results suggest that leflunomide may prevent the differentiation of Th17 cells in EAU.
By flow cytometric analysis, fresh cells from PBMC (Fig. 6A–B), fresh cells from spleen(Fig. 6C–D). The numbers in the histograms indicate the percentages of cells that were double-positive for IL-17/CD4. Data are expressed as the mean±SD (n = 6). *P<0.05; **P<0.01; a, normal; b, vehicle; c, low-dose leflunomide (3 mg/kg); d, medium-dose leflunomide (6 mg/kg); e, high-dose leflunomide (12 mg/kg); f, CsA (10 mg/kg).
Discussion
This study clearly demonstrates that oral administration of leflunomide was capable of suppressing the ongoing development of autoimmune uveoretinitis in the eye. CsA and FK-506 (tacrolimus) have been previously determined to be effective in preventing the development of uveitis in the EAU rodent model [27], [28]. Leflunomide is a novel immunosuppressive agent that also acts through calcineurin inhibition [29].
In the present study, we observed that rats treated with the leflunomide were capable of suppressing the ongoing process of autoimmune uveoretinitis in the eye. In addition, we show that oral leflunomide was capable of suppressing the ongoing process of ocular inflammation in the rat model of EAU. Leflunomide was effective in preventing the development of severe, clinical EAU with doses as low as 3 mg/kg when administered daily starting from the day of immunization with IRBP. Furthermore, the retinal detachment, photoreceptor layer damage, edema, and severe infiltration of leukocytes in the posterior chamber and other pathologic markers of EAU were markedly suppressed in the leflunomide-treated rats. The amelioration of intraocular inflammation, supported by histopathologic evidence of this effect, suggests that leflunomide may be a useful suppression for ocular inflammatory conditions.
However, the mechanism to suppress ocular inflammation and the effect for systemic immune response remain unknown. With the recognition of Th17 immunoregulation [30], [31], the understanding of involvement of Th17 in ocular diseases like uveitis [32], [33] is increasing. Beside conventional immune cells, the contribution of resident tissue cells to the modulation of IL17 must not be overlooked. In this study, to elucidate the anti-inflammatory mechanism of the oral leflunomide, we measured the concentrations of inflammatory cytokines such as IFN-γand IL17. As shown, IL17 production was inhibited in the leflunomide preventive group eyes on day 14 after immunisation. Furthermore, both the level of IFN-γand IL17 were decreased in the leflunomide preventive groups serum on day 14 after immunisation. Taken together, our results indicate that oral leflunomide has the capacity to suppress effector inflammatory cells via inhibition of the inflammatory cytokine expression in the ocular tissue and serum.
CsA was used as the positive control because of its proven efficacy in preventing EAU formation and treating established EAU in the rodent model [34], [35], [36]. CsA was able to inhibit clinical symptom of uveitis and to decrease clinical signs of uveitis. Based on the clinical and histopathologic findings in this study, the therapeutic efficacy of leflunomide appears equal to cyclosporine.
The in vitro effects of leflunomide on lymphocytes suggest that its efficacy may be mediated through the inhibition of T-cell effector responses. Lymphocytes harvested from animals treated with leflunomide demonstrated significantly decreased antigen proliferation compared with untreated control animals. This finding was observed with the intragastric administration of 3 mg/kg/d dosing and also with higher doses. Leflunomide also demonstrated a dose-dependent ability to inhibit the proliferation of stimulated lymphocytes.
Th1 and Th17 cells are involved in autoimmune disorders. Pro-inflammatory Th1 and Th17 immune responses have been previously shown to be salient features of uveitis and scleritis [37], [38]. Th17 cells constitute a third subset of effector helper T cells. The effector functions of Th17 cells are distinct from those of Th1 and Th2 cells [7], [39], [40]. Th17 cells and IL-17 play a critical role in the pathogenic mechanisms of intraocular inflammation in an animal model of human uveitis [7], [41], [42]. In humans, the number of Th17 lymphocytes increases during acute uveitis or scleritis and decreases after treatment [32], [43], [44], [45], [46]. Indeed, EAU in rats is suppressed by anti–IL17 antibody [8]. In the present study, we showed that fresh intraocular T cells from immunized EAU donors had a large population of IL-17+cells, suggesting that CD4+IL-17+Th17-type T cells may be associated with the pathogenic mechanisms of intraocular inflammation. Importantly, spleen and PBMC CD4+EAU T cells produced less IL-17 if the rats were treated with leflunomide. Thus, leflunomide provides protection from inflammation by Th17-type helper T cells in EAU. This provides evidence that IL-17 plays a crucial role in EAU and that leflunomide reduces EAU severity by reducing Th17 responses. Our results indicate that oral leflunomide suppressed IL17 gene expression and IFN-γgene expression in the eyes of EAU rats. The decreased production of both Th1 and Th17 lymphocyte subsets, as evidenced by the decreased production of both IFN-gamma and IL17, can be explained by the decreased severity of EAU in rats pre-treated by leflunomide. The ability of leflunomide to downregulate pro-inflammatory Th1 and Th17 effector responses, combined with its efficacy in the prevention EAU. Leflunomide, an isoxazole derivative that is structurally unrelated to other immunomodulatory agents, interferes in multiple immunological pathways. Further investigations are needed to clarify the mechanism of leflunomide effect on immune cells. The dosage of leflunomide in rats used in the experiment was generally well-tolerated [14], [19], [47]. All experimental rats in leflunomide-treated group survived the experiment. We observed leflunomide side effects mostly in the high dose group such as weight loss and hairs sparseness.
In summary, we have demonstrated that oral leflunomide diminishes ocular inflammation by inhibiting pathogenic T-cell expansion and cytokine production in EAU. The protective effect of leflunomide on the development of EAU suggests that leflunomide might be an attractive potential therapeutic approach for the treatment of autoimmune disease.
Author Contributions
Helpful suggestions: CH. Conceived and designed the experiments: CBF JL. Performed the experiments: CBF DXZ SXZ ZL. Analyzed the data: CBF. Contributed reagents/materials/analysis tools: CBF YH. Wrote the paper: CBF.
References
- 1. Bansal R, Gupta V, Gupta A (2010) Current approach in the diagnosis and management of panuveitis. Indian J Ophthalmol 58: 45–54.
- 2. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, et al. (2005) Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol 140: 45–51.
- 3. Takeuchi M, Iwasaki T, Kezuka T, Usui Y, Okunuki Y, et al. (2010) Functional and morphological changes in the eyes of Behcet’s patients with uveitis. Acta Ophthalmol 88: 257–262.
- 4. Smith JR, Verwaerde C, Rolling F, Naud MC, Delanoye A, et al. (2005) Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther 16: 1037–1046.
- 5. Camelo S, Lajavardi L, Bochot A, Goldenberg B, Naud MC, et al. (2009) Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 25: 9–21.
- 6. Kowalczuk L, Touchard E, Camelo S, Naud MC, Castaneda B, et al. (2009) Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle. Invest Ophthalmol Vis Sci 50: 1761–1768.
- 7. Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y, Ishibashi T, et al. (2008) Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 20: 209–214.
- 8. Zhang R, Qian J, Guo J, Yuan YF, Xue K (2009) Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody. Curr Eye Res 34: 297–303.
- 9. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233–240.
- 10. Commodaro AG, Bombardieri CR, Peron JP, Saito KC, Guedes PM, et al. (2010) p38{alpha} MAP kinase controls IL-17 synthesis in vogt-koyanagi-harada syndrome and experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 51: 3567–3574.
- 11. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677–688.
- 12. Schattenkirchner M (2000) The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review. Immunopharmacology 47: 291–298.
- 13. Johansen A, Jensen JE, Horn HC, Nielsen B, Kemp E (1998) Effect of leflunomide and cyclosporine on graft survival and changes in lymphocyte phenotypes in a rat heart allotransplantation model. Transpl Immunol 6: 48–52.
- 14. He C, Lu X, Yan Z, Wu M, Liu S, et al. (2012) Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int 32: 633–638.
- 15. Korn T, Toyka K, Hartung HP, Jung S (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124: 1791–1802.
- 16. Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT (1995) The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 272: 460–468.
- 17. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, et al. (1995) The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 275: 1043–1049.
- 18. Quemeneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, et al. (2003) Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 170: 4986–4995.
- 19. Robertson SM, Lang LS (1994) Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 42: 167–172.
- 20. Varron L, Abad S, Kodjikian L, Seve P (2011) Sarcoid uveitis: Diagnostic and therapeutic update. Rev Med Interne 32: 86–92.
- 21. Roy M (2007) Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 42: 634.
- 22. Korn T, Magnus T, Toyka K, Jung S (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide–mechanisms independent of pyrimidine depletion. J Leukoc Biol 76: 950–960.
- 23. Stosic-Grujicic S, Dimitrijevic M, Bartlett R (1999) Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes. Clin Exp Immunol 117: 44–50.
- 24. Agarwal RK, Caspi RR (2004) Rodent models of experimental autoimmune uveitis. Methods Mol Med 102: 395–419.
- 25. Chan CC, Caspi RR, Ni M, Leake WC, Wiggert B, et al. (1990) Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun 3: 247–255.
- 26.
Caspi RR (2003) Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol Chapter 15: Unit 15 16.
- 27. Kawashima H, Fujino Y, Mochizuki M (1988) Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 29: 1265–1271.
- 28. Oh-i K, Keino H, Goto H, Yamakawa N, Murase K, et al. (2007) Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. Br J Ophthalmol 91: 237–242.
- 29. Egli A, Kohli S, Dickenmann M, Hirsch HH (2009) Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation 88: 1161–1168.
- 30. Peters A, Lee Y, Kuchroo VK (2011) The many faces of Th17 cells. Curr Opin Immunol 23: 702–706.
- 31. Wilke CM, Bishop K, Fox D, Zou W (2011) Deciphering the role of Th17 cells in human disease. Trends Immunol 32: 603–611.
- 32. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, et al. (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711–718.
- 33. Hamzaoui K (2011) Th17 cells in Behcet’s disease: a new immunoregulatory axis. Clin Exp Rheumatol 29: S71–76.
- 34. Liu X, Yang P, Lin X, Ren X, Zhou H, et al. (2009) Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol 131: 333–342.
- 35. Chi W, Yang P, Zhu X, Wang Y, Chen L, et al. (2010) Production of interleukin-17 in Behcet’s disease is inhibited by cyclosporin A. Mol Vis. 16: 880–886.
- 36. Nussenblatt RB, Rodrigues MM, Wacker WB, Cevario SJ, Salinas-Carmona MC, et al. (1981) Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 67: 1228–1231.
- 37. Chi W, Yang P, Li B, Wu C, Jin H, et al. (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119: 1218–1224.
- 38. Yang Y, Xiao X, Li F, Du L, Kijlstra A, et al. (2012) Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 53: 1012–1017.
- 39. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.
- 40. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179–189.
- 41. Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, et al. (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 48: 347–354.
- 42. Cui Y, Shao H, Lan C, Nian H, O’Brien RL, et al. (2009) Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells. J Immunol 183: 560–567.
- 43. Murray PI, Clay CD, Mappin C, Salmon M (1999) Molecular analysis of resolving immune responses in uveitis. Clin Exp Immunol 117: 455–461.
- 44. Murphy CC, Duncan L, Forrester JV, Dick AD (2004) Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol 88: 412–416.
- 45. Luger D, Silver PB, Tang J, Cua D, Chen Z, et al. (2008) Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205: 799–810.
- 46. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121–1133.
- 47. Jin D, Duan K, Zhang L, Peng J, Zhao Y (2012) The effects of leflunomide on CD4(+)CD25 (+)Foxp3 (+) T regulatory cells in mice receiving allogeneic bone marrow transplantation. Inflamm Res 61: 53–60.